Study to Investigate a New Drug in Healthy Subjects of Different Races
Research type
Research Study
Full title
A Phase 1 open-label study to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of ASP3652 in Caucasian, Japanese, Black/African and Chinese healthy male and female subjects
IRAS ID
109585
Contact name
Muna Albayaty
Sponsor organisation
Astellas Pharma Global Development - Europe
Eudract number
2012-001476-11
Research summary
ASP3652 is being investigated as a novel treatment for chronic pelvic pain. This study will be performed at the PAREXEL Early Phase Clinical Unit (London), Northwick Park Hospital, Watford Road, Harrow, HA1 3UJ. The study is an open-label study to assess the pharmacokinetics (how the study drug is taken up, metabolised [chemically broken down in the body], distributed through the body and excreted), pharmacodynamics (levels of biochemical markers in the bloodstream), safety and tolerability of a single dose of ASP3652 in healthy male and female subjects from Caucasian, Japanese, Black/African and Chinese origin. A total of 64 healthy male and female subjects will be included in this study (16 subjects per race group). Each race group will comprise of 8 female subjects and 8 male subjects. For each race group, plasma samples for PK and PD analysis will be collected and vital signs, safety ECG measurements, safety laboratory assessments, adverse events (AEs) and concomitant medications will be monitored throughout the entire investigational period.
REC name
East of England - Cambridgeshire and Hertfordshire Research Ethics Committee
REC reference
12/EE/0302
Date of REC Opinion
25 Jul 2012
REC opinion
Further Information Favourable Opinion